Adalimumab 40 mg sc every other week (DrugBank: Adalimumab)
16 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
19 | Lysosomal storage disease | 0 |
37 | Generalised pustular psoriasis | 0 |
40 | Takayasu arteritis | 0 |
41 | Giant cell arteritis | 0 |
46 | Malignant rheumatoid arthritis | 0 |
56 | Behcet disease | 0 |
84 | Sarcoidosis | 0 |
96 | Crohn disease | 0 |
97 | Ulcerative colitis | 0 |
151 | Rasmussen encephalitis | 0 |
160 | Congenital ichthyosis | 0 |
164 | Oculocutaneous albinism | 0 |
222 | Primary nephrotic syndrome | 0 |
226 | Interstitial cystitis with Hunners ulcer | 0 |
269 | Pyogenic arthritis | 0 |
271 | Ankylosing spondylitis | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00235105 (ClinicalTrials.gov) | March 2005 | 6/10/2005 | D2E7-Early AS | Adalimumab in Early Axial Spondyloarthritis (Without Radiological Sacroiliitis): Placebo Controlled Phase Over 3 Months Followed by a 9 Months Open Extension Phase | Ankylosing Spondylitis | Drug: Adalimumab 40 mg sc every other week | Charite University, Berlin, Germany | Abbott | Active, not recruiting | 18 Years | N/A | Both | 46 | Phase 2;Phase 3 | Germany |